What Triumvira Immunologics does

Triumvira Immunologics is a privately held, clinical-stage immuno-oncology company founded in 2015 that develops engineered T cell therapies for cancer using its proprietary T cell Antigen Coupler (TAC) platform. The TAC technology is a multi-domain chimeric receptor — incorporating an antigen-binding domain, a CD3-binding domain, and a unique CD4 co-receptor domain — that activates patient-derived T cells by co-opting the endogenous T cell receptor complex rather than replacing or gene-editing it. This architecture is intended to enable selective tumor recognition independent of MHC, normal immune synapse formation, controlled cytokine release, deep tumor penetration, and reduced T cell exhaustion, positioning TAC as a differentiated alternative to CAR-T and engineered TCR approaches.

The company's lead clinical candidate, TAC101-CLDN18.2, is in Phase I/II development (TACTIC-3, NCT05862324) for CLDN18.2-positive solid tumors including gastric, gastroesophageal junction, esophageal adenocarcinoma, pancreatic ductal adenocarcinoma, colorectal, cholangiocarcinoma, ovarian mucinous, gallbladder, and non-small cell lung cancers. The broader pipeline targets additional antigens (GPC3, GUCY2C) and includes an allogeneic 'off-the-shelf' program using non-gene edited gamma delta T cells. Triumvira has no commercial revenue; its go-to-market motion is clinical-stage, generating proof-of-concept through academic medical center trial sites (including MD Anderson Cancer Center) and presenting data at major oncology conferences (ASCO, SITC). Manufacturing is enabled through a strategic partnership with Lonza using the Cocoon platform, intended to support scalable, point-of-care autologous production.

The company is backed by dedicated healthcare investors — Leaps by Bayer, Northpond Ventures, and B Capital among them — with approximately $100M raised cumulatively through Series B rounds in 2020 and 2022. Leadership is headed by President and CEO Paul Lammers, with scientific co-founder Jonathan Bramson, PhD, serving as Chief Scientific Officer and Chair of the Scientific Advisory Board. The company maintains headquarters in San Francisco and operational offices in Austin, San Diego, and Hamilton, Ontario. Future revenue, if any, is expected to derive from product sales post-approval or from out-licensing transactions with larger pharmaceutical partners.

Name

Triumvira Immunologics

Legal name

Triumvira Immunologics Inc.

Website

https://triumvira.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Triumvira Immunologics is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapies based on its proprietary TAC receptor platform, with lead candidate TAC101-CLDN18.2 in Phase I/II trials for CLDN18.2-positive solid tumors.

Ownership category

akta.pro rank

Product category

Cell Therapy / Immuno-Oncology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• T cell therapy
• Cell therapy platform
• Immuno-oncology
• Autologous cell therapy
• Allogeneic cell therapy

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. TAC-T Cell Therapeutics: Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics. The company is not yet revenue-generating as its lead product candidate TAC101-CLDN18.2 is still in Phase I/II clinical trials (TACTIC-3). Future revenue would likely come from product sales following regulatory approval or from out-licensing partnerships with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Triumvira Immunologics is a clinical-stage immuno-oncology company developing novel T cell therapies for cancer using its proprietary T cell Antigen Coupler (TAC) platform. The company's lead candidate TAC101-CLDN18.2 is an autologous cell therapy currently in Phase I/II clinical trials (TACTIC-3) for Claudin 18.2-positive solid tumors. Triumvira is also developing allogeneic TAC-T cell programs using gamma delta T cells and pursuing out-licensing partnerships with larger pharmaceutical companies.

Product overview

Triumvira Immunologics is a clinical-stage immuno-oncology company developing T cell therapies based on its proprietary T cell Antigen Coupler (TAC) platform. The company's core product is TAC101-CLDN18.2, an autologous cell therapy targeting Claudin 18.2-positive solid tumors currently in Phase I/II clinical trials (TACTIC-3). The TAC platform is a multi-domain chimeric molecule technology that co-opts natural T cell biology by working with the endogenous T cell receptor, offering potential advantages over CAR-T and TCR therapies for treating solid tumors. The company is also developing allogeneic approaches using gamma delta T cells.

Differentiator

Problem solved

Functional benefit

Products and services

• TAC101-CLDN18.2 An autologous T cell therapy based on the proprietary TAC platform that redirects patient-derived T cells to target and eliminate Claudin 18.2 (CLDN18.2)-positive solid tumor cells. Currently in Phase I/II clinical trials (TACTIC-3, NCT05862324) for indications including gastric, GEJ, esophageal adenocarcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, cholangiocarcinoma, ovarian mucinous cancer, gallbladder cancer, and NSCLC.
• Allogeneic TAC-T Cells (Gamma Delta T Cells) An off-the-shelf allogeneic cell therapy approach using non-gene edited gamma delta (γδ) T cells from healthy donors, engineered with the TAC technology. Designed as an alternative to autologous patient-derived cells for scalable cancer treatment.

Quantifiable outcome

• Preliminary safety and promising clinical activity observed in Phase I TACTIC-3 study at lower dosages, even among patients who have undergone multiple prior treatments
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and minor.

• LonzacoreStrategic or Co-development PartnerTriumvira is working with Lonza, a leading global T cell manufacturer, to develop autologous TAC-T cell products using their state-of-the-art, automated and self-contained Cocoon™ Manufacturing System. The company believes the Cocoon has the potential to become a point-of-care system for developing autologous cell therapy approaches. This is a risk-sharing collaboration focused on scalable manufacturing.
• Top-tier pharmaceutical and cell therapy companiesminorStrategic or Co-development PartnerEvaluation partners including top-tier pharmaceutical and cell therapy companies have independently validated the TAC technology in preclinical models of cancer. Through comparative evaluations of TAC-T cells and CAR-T cells across multiple tumor models, the company seeks to identify out-licensing opportunities.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson serves as a clinical trial site for the TACTIC-3 Phase I/II study. Dr. Ecaterina E. Dumbrava, Assistant Professor in the Department of Investigational Cancer Therapeutics, presented preliminary clinical data from the trial.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adaptimmune Therapeutics: Develops engineered T cell receptor (TCR) therapies for solid tumors. Most directly comparable to Triumvira because both companies focus on receptor-engineered T cell approaches (rather than CAR-T) targeting solid tumor antigens with a similar clinical-stage profile.
• Iovance Biotherapeutics: Develops tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a clinical-stage cell therapy company targeting the same unmet need (cell therapy for solid tumors) with similar regulatory and manufacturing complexity.
• Allogene Therapeutics: Pioneers allogeneic CAR-T cell therapies. Comparable because Triumvira is also developing an allogeneic gamma-delta TAC-T cell program, and both companies face similar manufacturing and platform-scaling challenges in the engineered T cell therapy space.
• Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a clinical-stage engineered T cell therapy peer pursuing allogeneic approaches with similar capital intensity and partnership dynamics.
• Fate Therapeutics: Develops iPSC-derived off-the-shelf cell therapies including NK and T cell candidates. Comparable as a clinical-stage cell therapy peer pursuing novel modalities (akin to Triumvira's TAC) for oncology with similar scientific and manufacturing risk profiles.
• Cellectis: Clinical-stage biotech developing allogeneic CAR-T therapies using gene editing. Comparable as a clinical-stage engineered T cell therapy peer with similar pipeline breadth, manufacturing complexity, and partnership-driven business model.

Broad incumbents

• Novartis (Kymriah): Global pharmaceutical company with Kymriah, the first approved CAR-T therapy. Comparable as a large incumbent setting benchmarks in cell therapy safety, manufacturing, and commercialization against which Triumvira's TAC platform will ultimately be evaluated.
• Gilead Sciences (Kite Pharma): Owns Kite Pharma, a leader in approved CAR-T therapies (Yescarta, Tecartus). Comparable as a broad incumbent in cell therapy with deep manufacturing infrastructure and commercial reach that Triumvira would likely partner with or compete against.
• Bristol-Myers Squibb (Breyanzi, Abecma): Major pharmaceutical company with approved CAR-T therapies (Breyanzi for lymphoma, Abecma for multiple myeloma). Comparable as a broad incumbent in cell therapy with established clinical, regulatory, and commercial capabilities.
• Astellas Pharma: Pharmaceutical company that received FDA approval for zolbetuximab (Vyloy), the first approved CLDN18.2-targeted therapy. Comparable because Astellas directly competes with Triumvira's TAC101-CLDN18.2 program in CLDN18.2-positive gastric and GEJ cancers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/Triumvirainc
• LinkedInlinkedin.com/company/triumvira-immunologics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triumvira Immunologics